MSD secures full approval for Keytruda’s use in MSI-high solid tumours
Pharmaceutical Technology
MARCH 30, 2023
There, the FDA suggested that the drugs undergo randomised controlled trials, which the document describes as the preferred approach, rather than single-arm trials. While the drug was granted accelerated approval in June 2019, it did not deliver on a key overall survival (OS) endpoint as part of its post-marketing data package.
Let's personalize your content